An Open-Label Study of Atomoxetine in Adolescents With Attention-Deficit/Hyperactivity Disorder

NCT00191737 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

147

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

DRUG: Atomoxetine

Sponsor

Eli Lilly and Company